{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:20:31Z","timestamp":1771266031941,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00774-018-0917-0","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T10:47:17Z","timestamp":1520506037000},"page":"301-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Katsuhiko","family":"Nakatsukasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"key":"917_CR1","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1200\/JCO.2001.19.10.2596","volume":"19","author":"H Mouridsen","year":"2001","unstructured":"Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596\u20132606","journal-title":"J Clin Oncol"},{"key":"917_CR2","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ, Panel members (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736\u20131747. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdr304","journal-title":"Ann Oncol"},{"key":"917_CR3","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.2009.23.1274","volume":"28","author":"M Dowsett","year":"2010","unstructured":"Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509\u2013518. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.1274","journal-title":"J Clin Oncol"},{"key":"917_CR4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC, LATTE Investigators (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135\u20131141. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(10)70257-6","journal-title":"Lancet Oncol"},{"key":"917_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","volume":"369","author":"RC Coombes","year":"2007","unstructured":"Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE et al (2007) Survival and safety of exemestane versus tamoxifen after 2\u20133\u00a0years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559\u2013570","journal-title":"Lancet"},{"key":"917_CR6","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"B Thurlimann","year":"2005","unstructured":"Breast International Group (BIG) 1-98 Collaborative Group, Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747\u20132757","journal-title":"N Engl J Med"},{"key":"917_CR7","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1200\/JCO.2006.08.8054","volume":"25","author":"M Kaufmann","year":"2007","unstructured":"Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 25:2664\u20132670","journal-title":"J Clin Oncol"},{"key":"917_CR8","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra023246","volume":"348","author":"IE Smith","year":"2003","unstructured":"Smith IE, Dowsett M (2003) Aromatase inhibitors in breast cancer. N Engl J Med 348:2431\u20132442","journal-title":"N Engl J Med"},{"key":"917_CR9","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1083\/jcb.145.3.527","volume":"145","author":"TL Burgess","year":"1999","unstructured":"Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL (1999) The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527\u2013538","journal-title":"J Cell Biol"},{"key":"917_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165\u2013176","journal-title":"Cell"},{"key":"917_CR11","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci USA 95:3597\u20133602","journal-title":"Proc Natl Acad Sci USA"},{"key":"917_CR12","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","volume":"26","author":"GK Ellis","year":"2008","unstructured":"Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875\u20134882. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.16.3832","journal-title":"J Clin Oncol"},{"key":"917_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-017-0884-x","author":"K Nakatsukasa","year":"2017","unstructured":"Nakatsukasa K, Koyama H, Ouchi Y (2017) Effect of denosumab administration on low bone mineral density (T-score \u2212\u00a01.0 to \u2212\u00a02.5) in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer. J Bone Miner Metab. \n                    https:\/\/doi.org\/10.1007\/s00774-017-0884-x","journal-title":"J Bone Miner Metab"},{"key":"917_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet 386:433\u2013443. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)60995-3","journal-title":"Lancet"},{"key":"917_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00198-009-0970-6","volume":"21","author":"T Suzuki","year":"2010","unstructured":"Suzuki T, Yoshida H (2010) Low bone mineral density at femoral neck is a predictor of increased mortality in elderly Japanese women. Osteoporos Int 21:71\u201379","journal-title":"Osteoporos Int"},{"key":"917_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/00001648-199103000-00005","volume":"2","author":"ES Fisher","year":"1991","unstructured":"Fisher ES, Baron JA, Malenka DJ, Barrett JA, Kniffin WD, Whaley FS, Bubolz TA (1991) Hip fracture incidence and mortality in New England. Epidemiology 2:116\u2013122","journal-title":"Epidemiology"},{"key":"917_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2105\/AJPH.79.3.274","volume":"79","author":"J Magaziner","year":"1989","unstructured":"Magaziner J, Simonsick EM, Kashner TM, Hebel JR, Kenzora JE (1989) Survival experience of aged hip fracture patients. Am J Public Health 79:274\u2013278","journal-title":"Am J Public Health"},{"key":"917_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/BF02484420","volume":"18","author":"RP Pitto","year":"1994","unstructured":"Pitto RP (1994) The mortality and social prognosis of hip fractures. A prospective multifactorial study. Int Orthop 18:109\u2013113","journal-title":"Int Orthop"},{"key":"917_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00774-005-0654-z","volume":"24","author":"S Muraki","year":"2006","unstructured":"Muraki S, Yamamoto S, Ishibashi H, Nakamura K (2006) Factors associated with mortality following hip fracture in Japan. J Bone Miner Metab 24:100\u2013104","journal-title":"J Bone Miner Metab"},{"key":"917_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73\u201382","journal-title":"Crit Rev Oncol Hematol"},{"key":"917_CR21","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2007.11.0726","volume":"26","author":"R Eastell","year":"2008","unstructured":"Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G (2008) Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26:1051\u20131057","journal-title":"J Clin Oncol"},{"key":"917_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","volume":"19","author":"WX Qi","year":"2014","unstructured":"Qi WX, Tang LN, He AN, Yao Y, Shen Z (2014) Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 19:403\u2013410. \n                    https:\/\/doi.org\/10.1007\/s10147-013-0561-6","journal-title":"Int J Clin Oncol"},{"key":"917_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"D Kendler","year":"2010","unstructured":"Kendler D, Roux C, Benhamou C, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 25:72\u201381","journal-title":"J Bone Miner Res"},{"key":"917_CR24","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, Moffett A, Siddhanti S, Ferreira I, Ghelani P, Wagman RB, Hall JW, Bolognese MA, Benhamou CL (2013) Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol 121:1291\u20131299","journal-title":"Obstet Gynecol"},{"key":"917_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP (2014) Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone 58:48\u201354","journal-title":"Bone"},{"key":"917_CR26","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciuli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163\u20133170","journal-title":"J Clin Endocrinol Metab"},{"key":"917_CR27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10549-012-1973-0","volume":"133","author":"Shunji Takahashi","year":"2012","unstructured":"Takahashi Shunji, Iwase Takuji, Kohno Norio, Ishikawa Takashi, Taguchi Tetsuya, Takahashi Masato, Horiguchi Jun, Nakamura Seigo, Hozumi Yasuo, Fukunaga Masao, Noguchi Shinzaburo (2012) Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results. Breast Cancer Res Treat 133:685\u2013693","journal-title":"Breast Cancer Res Treat"},{"key":"917_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ctrv.2011.09.003","volume":"38","author":"M Gnant","year":"2012","unstructured":"Gnant M, Cl\u00e9zardin P (2012) Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev 38:407\u2013415. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2011.09.003","journal-title":"Cancer Treat Rev"},{"key":"917_CR29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomized trials. Lancet 386:1353\u20131361","journal-title":"Lancet"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-018-0917-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-018-0917-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-018-0917-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T10:18:17Z","timestamp":1567073897000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-018-0917-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["917"],"URL":"https:\/\/doi.org\/10.1007\/s00774-018-0917-0","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,8]]},"assertion":[{"value":"21 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board of Kyoto Prefectural University of Medicine, on January 10, 2014, and the conducted in accordance with the Helsinki Declaration of 1975, as revised in 1983. This study was registered with the UMIN Clinical Trial Registry (UMIN-CTR, UMIN000027425). Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}